TORONTO, ONTARIO–(Marketwired – April 17, 2014) – Arch Biopartners Inc (“Arch” or the “Company”) (CNSX:ACH)(OTCBB:FOIFF) announced today the board has appointed Claude Allary as an interim director.
Mr.
Press Releases
Arch Biopartners Enters Option to License University of Cincinnati Patent for Treating Bacterial Respiratory Infections
TORONTO, ONTARIO–(Marketwired – March 28, 2014) – Arch Biopartners Inc (Arch) or (the Company) (CSE:ACH)(OTCBB:FOIFF) announced today it has entered into a one year option agreement with the University of Cincinnati (UC) to exclusively license the commercial rights to a U.S.
Arch Biopartners Announcement
TORONTO, ONTARIO–(Marketwired – March 12, 2014) – With profound sadness, Arch Biopartners Inc. announces the passing of its Chairman, Jerry McElroy. The Board and management will miss his friendship, guidance and good judgment since the formation of the company.
Arch Biopartners Completes Private Placement and Receives NRC Funding
TORONTO, ONTARIO–(Marketwired – Feb. 25, 2014) – Arch Biopartners Inc (“Arch” or the “Company”) (CSE:ACH)(OTCBB:FOIFF) announced today it has raised $228,900 via a non-brokered private placement of 817,500 Units at a price of $0.28 per Unit.
Brain Tumor Cell Targeting Technology: Data to Be Presented at the Society of Neuro-Oncology Quadrennial Meeting
TORONTO, ONTARIO–(Marketwired – Nov. 20, 2013) – Arch Biopartners Inc (Arch) or (the Company) (CNSX:ACH)(OTCBB:FOIFF) announced today that data relating to proprietary technology identifying brain tumor targeting peptides developed by Dr. Stephen Robbins, Dr.
Arch Biopartners Appoints Former Roche Executives Patrick Smith and Craig Rayner as Drug Development Advisors
TORONTO, ONARIO–(Marketwired – Sept. 17, 2013) – Arch Biopartners Inc (Arch) or (the Company) (CNSX:ACH)(OTCBB:FOIFF) announced today Dr. Patrick Smith and Dr. Craig Rayner of d3 Medicine have been appointed drug development advisors to the Company.
Arch Biopartners Announces Issuance of U.S. Patent for Brain Tumor Cell Targeting Technology
TORONTO, ONTARIO–(Marketwired – Sept. 12, 2013) – Arch Biopartners Inc (Arch) or (the Company) (CNSX:ACH)(OTCBB:FOIFF) announced today that the U.S. Patent and Trademark Office has issued US Patent 8,530,429 protecting its peptide technology which targets brain tumour initiating cells (BTICs) and invasive glioma cells (IGCs).
Arch Biopartners Joins the Life Sciences Canadian Technology Accelerator in San Francisco
TORONTO, ONTARIO–(Marketwired – Aug. 14, 2013) – Arch Biopartners Inc (Arch) or (the Company)(CNSX:ACH) (OTCBB:FOIFF) announced today it has been accepted by the Consulate General of Canada, San Francisco/Silicon Valley to join the Life Sciences Canadian Technology Accelerator (CTA) at QB3 at the University of California San Francisco.
Arch Biopartners Announces Issuance of Additional U.S. Patent for Biofilm Inhibitor
TORONTO, ONTARIO–(Marketwired – June 6, 2013) – Arch Biopartners Inc (Arch) or (the Company) (CNSX:ACH) (OTCBB:FOIFF) announced today that the U.S. Patent and Trademark Office has issued an additional patent for an invention preventing or inhibiting the growth of biofilm formation on surfaces.
Brain Tumour Targeting Team Awarded Additional Funding
TORONTO, ONTARIO–(Marketwired – April 22, 2013) – Arch Biopartners Inc (“Arch” or the “Company”)(CNSX:ACH)(OTCBB:FOIFF) today announced Dr. Stephen Robbins and his co-collaborators have been awarded $750,000 from Alberta Innovates’ Collaborative Research and Innovation Opportunities (“CRIO”) Cancer Project to support his team’s ongoing work in developing new diagnostic and therapeutic treatments for malignant brain tumours.